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Method
Discovery and assessment of conserved Pax6 target
genes and enhancers
Pedro Coutinho,1 Sofia Pavlou, Shipra Bhatia, Kevin J. Chalmers, Dirk A. Kleinjan,
and Veronica van Heyningen
Medical Research Council (MRC) Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
The characterization of transcriptional networks (TNs) is essential for understanding complex biological phenomena such
as development, disease, and evolution. In this study, we have designed and implemented a procedure that combines in
silico target screens with zebrafish and mouse validation, in order to identify cis-elements and genes directly regulated by
Pax6. We chose Pax6 as the paradigm because of its crucial roles in organogenesis and human disease. We identified over
600 putative Pax6 binding sites and more than 200 predicted direct target genes, conserved in evolution from zebrafish to
human and to mouse. This was accomplished using hidden Markov models (HMMs) generated from experimentally val-
idated Pax6 binding sites. A small sample of genes, expressed in the neural lineage, was chosen from the predictions for
RNA in situ validation using zebrafish and mouse models. Validation of DNA binding to some predicted cis-elements was
also carried out using chromatin immunoprecipitation (ChIP) and zebrafish reporter transgenic studies. The results show
that this combined procedure is a highly efficient tool to investigate the architecture of TNs and constitutes a useful
complementary resource to ChIP and expression data sets because of its inherent spatiotemporal independence. We have
identified several novel direct targets, including some putative disease genes, among them Foxp2; these will allow further
dissection of Pax6 function in development and disease.
[Supplemental material is available for this article.]
Complex biological processes such as organogenesis require finely
tuned spatiotemporal regulation of multiple developmental path-
ways. This is achieved at a number of levels including transcrip-
tional regulation, translation control, and protein modification.
Recently, the deciphering of transcriptional networks (TNs) has
become feasible with the availability of multiple vertebrate ge-
nome sequences, the ever-increasing information on transcription
factor (TF) binding sites, and large biological data sets, such as
tissue-specific expression profiles. The combination of these types
of data with the concept of evolutionary conservation has led to
some successful studies identifying direct targets of selector gene
transcription (Mann and Carroll 2002), including those for eyeless,
the Drosophila Pax6 gene (Ostrin et al. 2006), and, in vertebrates,
targets of Atoh7 (Ath5) and Pax2/5/8 were identified and validated
in medaka (Del Bene et al. 2007; Ramialison et al. 2008).
We have developed a process that combines an in silico ap-
proach based on evolutionary conservation and the use of avail-
able experimentally tested binding sites to predict similar TF
binding sites genome-wide, followed by validation of predictions
in zebrafish and mouse. The known binding sites were extracted
from the literature and used to generate Pax6 binding site hidden
Markov models (HMMs) that allow genome-wide prediction of
a new set of putative Pax6 binding sites that are expected to
function as enhancers for genes regulated directly by Pax6. The
choice of Pax6 as a paradigm for this study was based on its im-
portant roles in development and in human disease. During de-
velopment, Pax6 is required for correct patterning of the nervous
system (Stoykova et al. 1996; Ericson et al. 1997; Engelkamp et al.
1999; Holm et al. 2007; Brill et al. 2008; Simpson et al. 2009), eyes
(Ashery-Padan et al. 2000;Marquardt et al. 2001), and pancreas (St-
Onge et al. 1997; Ashery-Padan et al. 2004).
PAX6 haploinsufficiency in humans results predominantly in
eye anomalies such as aniridia, lenticular-corneal adhesions (van
Heyningen andWilliamson 2002), and, rarely, microphthalmia (V
van Heyningen, pers. comm.). In some cases, cognitive impair-
ment (Heyman et al. 1999; Ticho et al. 2006), mental retardation,
and cerebellar ataxia (Graziano et al. 2007) were reported. Struc-
tural and functional brain anomalies have also been observed
(Sisodiya et al. 2001; Mitchell et al. 2003; Bamiou et al. 2007).
Similar phenotypes are seen in animal models, such as the mouse
Pax6 mutant Smalleye (Hill et al. 1991; Estivill-Torrus et al. 2001;
Davis et al. 2003), In the mouse, homozygous loss of function was
shown to lead to anophthalmia, severe brain malformation, and
absence of olfactory system and endocrine pancreas function, all
leading to neonatal lethality. Additionally, mouse conditional in-
activation models provide further information on late functions
when early lethality of the full knockout precludes late studies
(Davis-Silberman et al. 2005; Tuoc et al. 2009). A pax6b missense
mutant sunrise (sri) has also been described in zebrafish, showing
a relatively mild eye phenotype seen only in homozygotes which
are viable and fertile (Kleinjan et al. 2008). However, morpholino-
induced knockdown of one or both zebrafish pax6 genes, pax6a
and pax6b, allows us to explore the role of these genes in early
embryonic development. Zebrafish is a particularly good model
to investigate eye development and disease because of the simi-
larity between zebrafish and human eyes, both at amolecular and
morphological level (Goldsmith and Harris 2003; Glass and
Dahm 2004; Fadool and Dowling 2008). In contrast to mice with
eyes specialized for nocturnal life, both zebrafish and humans
have evolved eyes for diurnal life including cone-dense retinas
(Goldsmith and Harris 2003), which are also biochemically more
similar than mouse to human retinas. For example, guanylate
cyclase activator 1a is expressed in zebrafish and human retinas
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but not in the mouse (Imanishi et al. 2002). Such species-specific
distinction is significant, given the clinical importance of cone
degeneration syndromes.
Several studies, aimed at better understanding the architec-
ture and diverse functions of Pax6 networks, have investigated
differential expression of potential target genes in specific tissues
and under various experimental conditions, including the use of
mutant versus wild type comparisons (Chauhan et al. 2002; Holm
et al. 2007; Visel et al. 2007; Sansom et al. 2009; Wolf et al. 2009).
PAX6 binding sites have been identified in mouse embryonic
cortex, using ChIP (Sansom et al. 2009). Comparison of the data
sets from these studies shows that there is not one fixed set of genes
regulated by Pax6 but several, depending on the spatiotemporal
environment. Although there is overlap, the majority of genes in
each target set are not present in other sets. Furthermore, binding
of Pax6 to a cis-enhancer does not always correlate with function;
for example, only 22% of the genes associated with adjacent Pax6
binding sites show expression level differences in the cortex when
Pax6 levels are altered (Sansom et al. 2009).
There is a need for Pax6 target screens that are not spatio-
temporally restricted, as these can complement and drive ‘‘wet’’
lab-based studies and be used as a theoretical framework to pre-
dict the Pax6 transcription networks, identifying genes that may
transmit andmodulate specific Pax6 functions in different tissues
or cell types at different stages of the life cycle.
Results
In silico identification and analysis of Pax6 targets
To achieve better insight into the role of Pax6 in neuronal de-
velopment, particularly eye development, we began by manually
annotating experimentally validated Pax6 binding sites (BSs) from
research articles in PubMed. From these, we identified 29 binding
sites. Close inspection of the BSs showed that there is only a low
degree of similarity between some of these (Supplemental Fig. S1).
This led us to develop a semiautomated procedure to identify a
reasonable number of BSs with a relatively high level of similarity
(Supplemental Fig. S2A,B). These were used to make a HMM to
identify the best matches among the remaining ones. This process
was iterated until the best new matches were deemed too deviant,
by visual inspection.
This selection procedure retrieved 16 similar Pax6 BSs (Sup-
plemental Fig. S2B) which were used to compare HMM- and po-
sition weight matrices (PWM)-based strategies. PWM and HMM
were generated and run, using parallel procedures (as described in
Fig. 1A for HMMs). The results show that both strategies are largely
equivalent for high stringency levels, but the use of HMMs com-
bined with thresholds based on experimentally validated BSs is, at
least computationally, more stringent (Supplemental Fig. S3A–D).
Using the selected BSs, we then generated species-specific
HMM models and used these (Fig. 1A) in combination with the
HMMER software package (Fig. 1B ; Eddy 1998) to identify pre-
dicted BSs genome-wide within transcribed regions, excluding
exonic regions but covering 20 kb on either side of each tran-
scription unit. This thresholded process revealed two lists of pu-
tative BSs at sites showing evolutionary conservation from zebra-
fish to human and zebrafish to mouse. We identified 874 human
and 1032 mouse putative BSs, corresponding to 903 and 746
zebrafish BSs, respectively. Applying the stringent criterion that
BSs have to be at least 40 bp distant from other predicted BSs, re-
duced these numbers to 654 human and 819 mouse BSs, and 813
and 640 in zebrafish, respectively (Supplemental Table S4). The
predicted BSs can be assigned to 327 human genes and 272 mouse
genes, corresponding to 356 and 269 zebrafish genes, respectively
(Supplemental Table S4). Inspection of the list of zebrafish putative
target genes shows that 48% (202 genes) are found in both the
human/zebrafish and mouse/zebrafish conserved sets. Of the re-
mainder, 16% (67 genes) are mouse/zebrafish specific and 36%
(154 genes) are human/zebrafish specific (Fig. 1C). The full anno-
tated lists of BSs within human andmouse gene homologues, with
chromosomal nucleotide positions, are shown in Supplemental
Tables S5–S8. Gene targets that coincide between the two mam-
mals are highlighted in yellow. Multiple binding sites associated
with a single gene are clearly observed, reinforcing the concept of
homotypic clustering (Gotea et al. 2010).
To characterize the identified sets of mouse and human genes
at a functional level, we investigated gene ontology and expression
data. Gene ontology analysis shows enrichment, in both sets of
Figure 1. Bioinformatics approaches used to identify the PAX6 target
sites and the initial analysis of results. (A) Flow diagram of the HMM ap-
proach used to identify evolutionarily conserved direct targets of pax6.
The procedure to identify pax6 target enhancers and associated genes is
based on the screen of evolutionarily conserved noncoding genomic se-
quences from orthologous loci in zebrafish and human (ormouse). (B) The
screens were performed usingmodels based on pax6 binding sites or their
respective reverse complement sequences. (C ) 48% (202) of the putative
target genes were found in both pairwise comparisons, while 16% (67) are
mouse/zebrafish and 36% (154) human/zebrafish specific. (D) The full set
of human conserved target genes was analyzed using gene ontology. The
identified target genes are enriched for transcription factor activity and
developmental regulation as well as for neuron generation functions. The
x-axis represents the number of genes for each of the highest over-rep-
resented molecular function GO term which are named on the y-axis, and
the associated P-values are shown.
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predicted mammalian target genes, for the GO terms related to
embryonic development, patterning, and transcriptional regula-
tion (Fig. 1D; Supplemental Fig. S4). In addition, the set of human
genes was also highly enriched for genes involved in the genera-
tion of neurons (Fig. 2). Pax6 is known to be a key regulator of
central nervous system and eye development. To determine
whether the target sets were enriched for brain and eye specific
genes, we combined UniGene expression data analysis with
a bootstrap method to determine the statistical significance of the
findings. In our list of human genes, we found 192 eye- (P =
0.0456), 229 brain- (P = 0.0022), and 130 heart- (P = 0.7614) as-
sociated genes. Similarly, among the mouse genes, we found 133
eye (P = 0.8254), 154 brain (P = 0.1218), and 74 heart (P = 0.9758).
The P-values associated with the number of genes in each category
were computed relative to the full sets of mouse or humanUniGene
genes. Differences in the relative number of eye genes between the
two sets are discussed later. The overall results show enrichment in
eye and brain genes, while, for the control organ, the heart, there
was no significant enrichment. Therefore, our in silico procedure is
able to identify classes of genes, particularly in human data, that
play a role in the development of organs where Pax6 function is
crucial.
Characterization of pax6 morpholino models
While disruption of Pax6 function is known to be detrimental for
normal development in mouse and human, little is known about
the role of pax6 in zebrafish development. In zebrafish, there
are two pax6 paralogues (or co-orthologs), pax6a and pax6b. They
have partially overlapping expression patterns during early de-
velopment. Previously, we characterized a pax6b missense muta-
tion, sunrise (sri), which is homozygous viable and fertile (Kleinjan
et al. 2008). The pax6bsri/sri embryos, as well as adults, have a mild
phenotype with reduced lens size as the only obvious phenotype
(Kleinjan et al. 2008). To improve the characterization of pax6
function during zebrafish development and to establish a suitable
model for the validation of the in silico target gene results, we used
microinjection of morpholino oligonucleotide(s) at the 1–2-cell
stage (Nasevicius and Ekker 2000). Themorpholinoswere designed
to target the translation start sites of pax6a (pax6aMO) and pax6b
(pax6bMO), respectively (seeMethods and Supplemental Table S2).
Specificity of the morpholinos was addressed by designing
three distinct morpholinos against pax6a and 2 morpholinos
against pax6b. For both genes, the phenotypes that resulted from
the morpholino microinjections were highly similar, regardless of
which gene-specific morpholino was used. In addition, we con-
firmed, by western-blot analysis, that a reduction of Pax6 protein
level is observed in morpholino-injected embryos (Supplemental
Fig. S5). Unfortunately, microinjection of even very low doses of
pax6mRNA induces abnormalities (Kleinjan et al. 2008); therefore,
it was not possible to rescue the morpholino-induced phenotypes.
Embryos injected with pax6aMOor pax6bMO or both display
small body size, reduced neural tube girth, morphologically ab-
normal brain, and small eyes. All aspects of these phenotypes were
very robust, with >95% of the embryos exhibiting them (>>500
embryos were examined). The phenotype for pax6a knockdown
is slightly more severe than for pax6b, and the simultaneous
knockdown of both genes gives rise to a similar but even more
severe phenotype (Fig. 2).
Since decreases in body-, brain-, and eye-size, were obvious
phenotypes in the morpholino-injected embryos, we investigated
the levels of apoptosis and cell proliferation within the affected
tissues. No alteration in apoptosis levels (data not shown) was
observed, using Tunel assays, but we found abnormally high
maintenance of expression for two proliferationmarkers,myca and
ccnd1, within the eye and brain (Fig. 3), suggesting that injection of
the pax6 morpholinos gives rise to a proliferation defect that may
secondarily result in aberrant differentiation.
Validation of Pax6 target genes by whole-mount in situ analysis
Using morpholino knockdown of pax6a, pax6b, or both in em-
bryos, we set up a screen to validate experimentally some of the
computationally predicted targets, using whole-mount in situ
hybridization (WMISH) to assess gene expression. We used two
criteria to choose 15 putative target genes for testing: (1) known
expression in eye or brain, and (2) $2 predicted pax6 BSs at the
gene locus (Table 1). As Pax6 is known to play an important role in
early proliferation and differentiation, we chose to perform the
screen at 28 hpf (hours post fertilization). Many neuronal cells,
including those in the retina, are still proliferating at this stage.
Retinal ganglion cells, the first retinal cell type to differentiate
(Glass and Dahm 2004), have not yet begun to be generated. Not
all predicted binding sites are expected to be demonstrable at this,
or any other, single stage. Moreover,WMISHmay not reveal subtle
changes in gene expression in a subset of target cells within
strongly expressing tissues. Of the 15 genes tested, 10 (66.6%)
show altered expression in the morpholino-injected embryos
compared to sibling controls at 28 hpf. Eye and forebrain are the
structures most frequently affected, with seven genes showing
disrupted expression (arx, maf, foxp2, neurod, prox1, tcf7l2, and
tfap2a) (Fig. 4). Three predicted target genes showed altered neu-
ral tube expression—gata3, pax6b, and maf (Supplemental Fig.
S6)—and two were midbrain/hindbrain region genes: ptf1a and
pax6b (Supplemental Fig. S7). Among the set of genes with dis-
turbed eye or forebrain expression, Arx and Neurod1 have been
previously documented as direct or indirect PAX6 targets in the
mouse embryonic cortex (Visel et al. 2007). Expression of maf in
the lens disappears in themorphant embryos because the structure
is not present anymore. Tfap2a and Pax6 have been reported to co-
regulate lens development (Makhani et al. 2007) and, with Prox1,
theywere shown tomodulate Sox2 expression (Lengler et al. 2005).
Pax6misexpression is known to induceTcf7l2 in the diencephalon
(Matsunaga et al. 2000), and conversely, Tcf7l2 (previously named
Tcf4) diencephalon expression was found to be lost in Pax6-null
mice at E11.5 (Cho and Dressler 1998). These earlier data support
the validity of our method, but the majority of our direct target
predictions (Supplemental Tables S5–S8) is novel. For example, the
Figure 2. pax6 knockdown in zebrafish results in reduced size, partic-
ularly of nervous system structures. (A) Representative control sibling.
Knockdown with morpholino oligonucleotides at 1–2-cell stages of (B)
pax6a, (C ) pax6b, and (D) both pax6a and pax6b genes leading to
a phenotype with smaller eyes and reduced central nervous system
structures, e.g., neural tube, in comparison to control siblings The ab-
normal phenotype is present from early stages (24 hpf), and persists long
after 48 hpf (B–D). Treated embryos die before day 4.
Prediction and validation of Pax6 target genes
Genome Research 1351
www.genome.org
prediction of multiple BSs in the region of the foxp2 gene and the
observed alteration of expression in the tectum of morpholino-
injected embryos provide new evidence that pax6 plays a key role
in regulating critical neural function genes. In zebrafish, early
foxp2 expression is observed predominantly in the telencephalon,
but it is also seen at 36 hpf in the anterior commissure (Bonkowsky
andChien 2005), an interhemispheric connection that is absent in
a high proportion of aniridia patients with known heterozygous
PAX6 mutations (Sisodiya et al. 2001).
The design of the selection process, used to define the Pax6
targets predicted here, ensures that the BSs lie in evolutionarily
conserved elements. Therefore, we set out to study some of the
target genes that we had tested in zebrafish in the mouse, where
null mutants are available. Having noted the loss of Tcf7l2 di-
encephalon expression in homozygous Smalleye (Pax6/) mice
(Cho and Dressler 1998), we set out to investigate the expression
pattern of three other genes,Maf, Foxp2, and Tcfap2a, at E11.5, the
mouse developmental stage equivalent to 28 hpf in zebrafish. The
severity of the abnormalities in Pax6-null mice is generally greater
than seen in the double morpholino-treated zebrafish. For exam-
ple, the eye is absent inmutantmice.We found theMaf expression
level reduced in the neural tube of Pax6/ mice, just as it is in
pax6abMO zebrafish (Fig. 5A–D). Absence of Foxp2 expression
from the dorsolateral telencephalon (Fig. 5E–H) and of Tcfap2a
from the lateral diencephalic prosomere 1 was seen in Pax6/
embryos (Fig. 5I–L), mirroring the severe reduction of foxp2 and
tfap2 expression in the forebrain of pax6MO fish embryos.
Altered expressionof a predicted target gene in a knockdownor
null mutant embryo does not demonstrate that the gene is a direct
target. The specificity of the regulatory alteration is, however, em-
phasized by the fact that only some expression sites are affected. For
example, pax6MO zebrafish neurod expression is turned off in the
forebrain and eye but remains unaltered in the lateral line placodes
and in the pancreas bud (Supplemental in situ data).
Validation of Pax6 binding sites by chromatin
immunoprecipitation and reporter transgenesis
The expression pattern changes resulting from pax6 disruption,
together with the presence of evolutionarily conserved Pax6 BSs,
provide strong circumstantial evidence for direct regulation of
target genes by Pax6. To confirm that the regulation is direct, we
performed ChIP, using pax6-specific antibodies with chromatin
from 28-hpf zebrafish embryos. We selected two putative pax6 BSs
for each of five genes that show differential expression in pax6MO
and control embryos, plus two novel predicted BSs within the
pax6a locus. As a positive control, we used the pax6 BS in the sox2
enhancer N3 (Inoue et al. 2007) and, as negative control, a similar-
sized sequence, 1 kb upstream of N3, that we call N3neg. We also
chose to study two predicted pax6a enhancers, because Pax6 is
known to auto-regulate (Kleinjan et al. 2004; Manuel et al. 2007),
andwewanted to show that genes can be direct targets even if they
do not show a qualitative difference in our limitedWMISH screen.
Of the 12 BSs tested, one of the pax6a predicted BSs did not show
any enrichment. All the others showed enrichment that ranged
from almost twofold to 32-fold. These results demonstrate that the
combined procedure is highly accurate (Fig. 6A).
Finally, we examined functionally the role of the most in-
teresting and novel Pax6 target predicted, foxp2, using transient
reporter transgenics, in zebrafish. foxp2 ECR1 gave a robust pattern
of reporter expression at 28 hpf (Fig. 6B,D) when EGFP expression
Table 1. Binding sites and preserved or altered expression patterns of putative pax6 target genes
Ensembl ID Name
No. BSs,
in Dre
Altered
expression Eye Forebrain Midbrain Hindbrain
Neural
tube
ENSDARG00000004415 tcf7l2 14 + ne + ne ne ne
ENSDARG00000005453 foxp2 12 + ne + ne ne ne
ENSDARG00000045045 pax6a 7 - = = = = =
ENSDARG00000016526 gata3 6 + ne ne ne ne +
ENSDARG00000069737 pou4f2 6 - = = = = =
ENSDARG00000059279 tfap2a 5 + + + ne = =
ENSDARG00000021916 vax1 5 - = = = = ne
ENSDARG00000014479 ptf1a 4 + ne ne ne + ne
ENSDARG00000055158 prox1 3 + + ne ne ne ne
ENSDARG00000058011 arx 3 + ne + ne ne ne
ENSDARG00000019566 neurod 2 + + + ne ne ne
ENSDARG00000015890 maf 2 ne + = = = ne
ENSDARG00000045936 pax6b 2 + = = = + +
ENSDARG00000012667 tfap2b 2 - ne ne = = =
ENSDARG00000055283 id2a 2 - ne ne ne ne ne
(+) Altered; (-) preserved; (=) unaltered pattern; (ne) not expressed in this tissue at time of analysis.
Differential gene expression patterns observed for predicted pax6 targets at 28 hpf. Fifteen genes expressed in the eyes or brain, and with multiple
predicted pax6 BSs, were selected for experimental validation by WMISH. Expression in pax6-morpholino-injected embryos and control siblings is
reported to identify genes subject to modulation by pax6a or pax6b, at 28 hpf.
Figure 3. pax6a and pax6b knockdown causes abnormalmaintenance of
proliferation markers in the eye and CNS. (A,C) Normal expression of the
proliferationmarkersmyca and ccnd1 is down-regulated in the eye and CNS
by 32 hpf. (B,D) In embryos co-injected with pax6aMO and pax6bMO,
abnormal maintenance of expression of both markers is observed.
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was examined byWMISH. The pattern was consistent with the site
of expression of foxp2 in the brain (Fig. 6C,D) and was disrupted
either by mutation of the predicted pax6 BS (Fig. 6E) or by co-
injection of a mixture of pax6aMO with pax6bMO (Fig. 6F).
Discussion
We have developed a novel integrated procedure to characterize
the core architecture of transcriptional networks. While previous
studies have relied on the use of position
weightmatrices (Stormo2000) to identify
BSs, we decided to use profile HMM in-
stead. HMMs allow abstraction of the
probability distribution of the nucleo-
tides at each position, while PWMs are
based on the nucleotide distribution at
each BSs site separately, which incorrectly
assumes that these are independent. In
addition, HMMs are also better than
PWMs at identifying matches with small
indels or partial matches (Marinescu et al.
2005), and this capability has the poten-
tial to be useful for the identification of
noncanonical BSs. Moreover, we have
shown that for Pax6, the HMM approach
that we have taken gives more stringent
results than a similar PWM-based ap-
proach, using patser (Hertz and Stormo
1999). This high level of stringency is the
most adequate for use in transcriptional
studies focused on evolutionary tran-
scriptional conservation across relatively
large evolutionary distances, such as from
zebrafish to mammals. This is based on
the knowledge that transcriptional conservation is evolutionarily
relatively fast. For these reasons, studies such as ours are very useful
for highlighting the core of these networks, because they are spe-
cifically known to be under higher positive selection pressures
(Odom et al. 2007; Schmidt et al. 2010).
The possibility of identifying transcription factor BSs quickly
and defining the enhancers in which they reside and the genes
that are directly regulated by a given DNA binding transcription
factor, in combination with other types of data, such as gene ex-
pression profiles, allows us to reconstruct molecular networks and
identify new key modulators of development and disease. The
procedure is based on evolutionary conservation, and it is spatio-
temporally independent and can be used to define the genetic
framework in a wide range of experimental studies. Our aimwas to
identify enhancers linked to genes directly regulated by Pax6,
a proteinwhose function is essential for development andwhich is
disrupted in distinct forms of human disease. The identification of
a full spectrum of target genes will provide a better understanding
of the diversity of developmental processes in which Pax6 func-
tions and also directly pinpoint enhancers regulating target genes
whose disruption could potentially give rise to human disease or
disease susceptibility.
The evolutionarily conserved genomic loci analyzed in this
Pax6 target screen were restricted to sequence windows including
genes and +/ 20 kb flanking each gene. These distances were se-
lected for efficient scanning that covers ;80% of all intergenic
regions (Supplemental Fig. S8). It is alsowell established that a high
proportion of regulatory elements for one gene lie within one or
more introns of neighboring genes (Becker et al. 2007). It has also
been estimated in genome-wide association studies, carried out by
measuring allelic expression in lymphoblastoid cell lines, that <5%
of eQTLsmarked by SNPs lie >20 kb upstream of transcription start
sites (Veyrieras et al. 2008).
The screen has identified hundreds of novel putative Pax6 BSs
and the associated target genes. The gene sets are enriched for
transcription factor activity and the human/zebrafish conserved
set for neurogenesis. In addition, there is enrichment for genes
Figure 4. pax6a and pax6b knockdown disrupts the expression of pu-
tative target genes in the eye and brain. Of the 15 putative targets analyzed
by WMISH, seven display altered expression within the eye or brain, at 28
hpf: (A–D ) arx, (E–H ) maf, (I–L ) foxp2, (M–P ) neurod, (Q–T ) prox1, (U–X )
tcf7l2, (Y–AB ) tfap2a. The loss of expression of maf in the eye, B, illustrates
that loss of tissue (the lens) can lead to observed loss of gene expression.
Figure 5. pax6a and pax6b disruption causes similar expression pattern changes in mouse and
zebrafish. pax6a and pax6b morpholino knockdown in zebrafish and Pax6 null mutation in the mouse
lead to similar disturbance in expression pattern. (A–D) Maf (maf ) expression in the neural tube is re-
duced in both species when Pax6 (pax6a and pax6b) function is disrupted. (E–H) The prominent lateral
telencephalon expression domain of Foxp2 (foxp2) is severely reduced. (I–L) Tfap2a (tfpa2) expression in
prosomere 1 is abolished.
Prediction and validation of Pax6 target genes
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expressed in eye and brain, particularly between zebrafish and
human. The differences between the human andmouse sets in the
relative enrichment for eye-expressed genes are due to human eye
genes that may have mouse orthologues but are not present in the
mouse set of targets. This is probably due to a combinatorial effect
of evolutionary divergence of tissue-specific transcriptional regu-
lation (Odom et al. 2007; Schmidt et al. 2010) and specific evolu-
tionary pressures on the core Pax6 network resulting from the
closer similarity in visual function between human and zebrafish
than with the mouse (Fadool and Dowling 2008). In spite of these
species differences, the results are in agreement with known Pax6
functions, both as a selector gene and as a gene essential for both
proliferation and differentiation during development, particularly
for the neuronal lineage.
Owing to the lack of available null mutations for pax6a and
pax6b in zebrafish, we used morpholino oligonucleotides to induce
pax6 knockdown. Injection into early fertilized oocytes results in
embryos with smaller eyes and reduced
brain- and neural tube-phenotypes that
are similar to the mouse Smalleye model
and also fit inwith observations inhuman
PAX6 haploinsufficiency syndromes and
very rare compound heterozygotes (van
Heyningen and Williamson 2002). In
zebrafish, these outcomes may be the
consequence of a proliferation defect that
might also result in abnormal differentia-
tion, since cells acquire distinct fates, de-
pending on how long they are exposed
to morphogens (Dessaud et al. 2007). The
prolonged maintenance of proliferation
may result in increased exposure to mor-
phogenetic cues, which can impact on the
cell fate distribution (Duparc et al. 2007).
Thismight be a factor in the etiology of the
human PAX6mutant phenotype as well.
To validate the results of our Pax6
target identification procedure experi-
mentally, we chose 15 genes expressed in
the eye or brain, which are associatedwith
multiple predicted pax6 BSs. Ten of these
genes (66%) showed altered expression in
pax6MO embryos compared with controls
at 28 hpf, a stage that precedes retinal
differentiation. Three of these genes were
also assessed in E11.5 Pax6/ mouse
embryos where homozygous null mice
survive to birth. For all three genes, we
found equivalent expression pattern
changes in the zebrafish and mouse
models upon Pax6 disruption. Together
with the published Pax6-dependent reg-
ulation of predicted target gene Tcf7l2
(Cho and Dressler 1998), the collected
data allow us to conclude that our target
selection procedure is highly efficient in
finding Pax6 regulated genes and simul-
taneously delivers (part of) the evolu-
tionarily conserved regulatory network
that centers around this important selec-
tor gene.
To demonstrate direct regulation, we
were able to show, using ChIP with chromatin from 28-hpf
zebrafish embryos, that pax6 binds to selected targets, namely nine
predicted enhancers (corresponding to five validated genes) and to
a novel predicted enhancer from the pax6a locus. We found that
with the exception of one of the pax6a predicted enhancers, all of
the others tested bound Pax6, with up to 32-fold enrichment. The
pax6a results allow us to highlight that our validation screen is
a qualitative screen, and the experimental validation is stage-de-
pendent. Thus, although Pax6 binds one tested pax6a enhancer,
no alteration in the overall pax6a expression pattern was detected
in pax6MO embryos. Furthermore, the genes that do not show
altered expression patterns at 28 hpf may be active targets of pax6
at different stages, including in adult tissues.
For Foxp2, the major novel Pax6 target, we complemented
the ChIP experiments by generating and analyzing transient re-
porter transgenics in zebrafish with the fopx2 ECR1 enhancer. This
element drives expression in the forebrain, in a region topologically
Figure 6. pax6 directly regulates the novel predicted enhancers. (A) Immunoprecipitation of chro-
matin from 28-hpf zebrafish embryos, using anti-Pax6 antibodies and control rabbit IgG, was followed
by real time PCR to confirm enrichment for predicted BSs. The Pax6 in vivo occupancy is site-dependent,
leading to enrichment values from two- to 32-fold (y-axis). The x-axis shows each tested Pax6 BS (ECR1
and ECR2 for six different target genes). (B) Summary expression data for the reporter transgenic
zebrafish embryos for foxp2 ECR1: wild type (wt), mutant (mut), and wild type with pax6a and pax6b
knockdown (wt+pax6(a+b)MO), showing specific forebrain, nonspecific, or no expression. (C ) foxp2
WMISH showing prominent expression in forebrain at 28 hpf. (D) foxp2 ECR1 wt reporter study
employing EGFPWMISH to reveal signal in subset of cells showing full foxp2 expression in C. (E) Absence
of forebrain EGFP expression when reporter driven by foxp2 ECR1 mutated at the pax6 binding site. (F )
Absence of EGFP reporter expression when pax6(a+b) expression is down-regulated by double mor-
pholino co-injection.
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equivalent to where Foxp2 is expressed (Fig. 5E) and overlaps with
Pax6 expression (Theil et al. 1999). This reporter transgenic ex-
pression pattern can be disrupted by either morpholino-driven
down-regulation of pax6 or bymutation of the putative ECR1 pax6
BS. Thus, the HMM approach developed here for target binding
site identification is very successful in identifying cis-elements in
core vertebrate transcriptional networks.
Uncovering direct interactions between regulatory genes and
their downstream targets is a vital step toward the discovery of the
gene regulatory networks that control development, patterning,
and maintenance of organ function. Here, we have used a com-
bined strategy of bioinformatic target prediction and both in vivo
and in vitro validation, using two different animal models, zebra-
fish and mouse, to reveal new players in the core networks in-
volving the developmental regulator Pax6. A number of genes that
are found on the target lists (Supplemental Tables S5–S8) are well-
established interactors or documented targets of Pax6. These in-
clude Pax2 (Schwarz et al. 2000), Dach1, Six3/Six6, Eya1 (Purcell
et al. 2005), andNr2e1 (Schuurmans et al. 2004). In addition, while
this work was in progress, Hoxd4-driven antero-posterior pattern-
ing in mouse and zebrafish was shown to be directly regulated by
Pax6/pax6 (Nolte et al. 2006). Similarly, a regulatory region of Six6
was shown to be directly bound by Pax6 (Tetreault et al. 2009).
Regulation of Ctnnd2 by Pax6was also reported (Zhang et al. 2010).
Moreover, in some instances, predicted targets have beendescribed
as upstream regulators of Pax6; for example, binding of homeo-
domain proteins Meis1/2 is required for Pax6 expression in lens
development (Zhang et al. 2002), while Pbx1binding is additionally
needed in murine (Zhang et al. 2006) and zebrafish (Delporte et al.
2008) pancreas. It is intriguing and instructive to find that these
genes are also predicted targets for Pax6 binding (Supplemental
Tables S5–S8), since there are many instances emerging where re-
ciprocal regulation is observed in transcription factor networks
(Kondoh and Kamachi 2010). One other important aspect to be
taken in consideration is that, although our screen is restricted to
a +/ 20-kb region (that is, a 40-kb distance between genes), in
some cases we have identified enhancers that are further away
than that within neighboring loci, e.g., ELP4 and WWOX harbor
enhancers for PAX6 and MAF, respectively (Jamieson et al. 2002;
Kleinjan et al. 2008). Knowing this, we have complemented our
human target list with the two proximal and distal neighboring
genes (Supplemental Table S5).
The reliability of the list of predicted targets is also empha-
sized by the significant frequency with which the genes appearing
in Supplemental Tables S5–S8 are found in reports of altered gene
expression studies describing comparison of the transcriptomes in
Pax6-null and wild type mice (Holm et al. 2007; Visel et al. 2007).
Although such lists include indirect targets, clearly the coincidence
of their appearance on these lists increases our confidence in
accepting them as real binding targets for Pax6. Another plausible
subset of target genes found in Supplemental Tables S5–S8 includes
geneswith a known role in human eye or neurological disease (e.g.,
choroideremia: CHM, retinoschisis: RS1, mental retardation: ARX,
glaucoma with associated anomalies: LMX1B) (OMIM—http://
www.ncbi.nlm.nih.gov/omim), or with other relevant phenotypes
in model systems (e.g., Arx, Barhl2, Emx2, Gbx2, Gli3, Lmx1b,
Mab21l2, Neurod1, Nr2e1, Nkx2-2, Pou3f2, Pou4f2, Six6, Vax1, Zic3)
(MGI— http://www.informatics.jax.org/). Disease and mouse phe-
notype reference numbers in OMIM and MGI are shown in Sup-
plemental Table S9.
Finally, it is important to remember that this HMM approach
only identifies a subset of predicted transcription factor binding
sites. As discussed, some of the 29 identified known Pax6 binding
sites were excluded by the strategy of selecting similar enough sites
to allow the generation of the HMM. Furthermore, there are some
additional known sites, such as the three well-defined Pax6-Sox2
co-binding sites (Kondoh and Kamachi 2010), each of which
contains a specified distinct Pax6-binding sequence. These are so
divergent from each other that they could not produce an HMM.
These results will form the basis for further exploration of the
many essential roles of PAX6 in development and human disease.
For example, one of the novel targets, FOXP2, is a protein known to
play a key role in language and speech functions (Fisher and
Scharff 2009). Interestingly, PAX6 haploinsufficiency has been
associated with structural and functional brain anomalies and
learning disability (Heyman et al. 1999; Sisodiya et al. 2001;
Bamiou et al. 2007; Graziano et al. 2007; Maekawa et al. 2009) and
with behavioral and functional brain changes in rodents, too (Tuoc
et al. 2009; Umeda et al. 2010). Another of the targets, TCF7L2, is
associated with Type 2 diabetes (Grant et al. 2006; Helgason et al.
2007; Scott et al. 2007). In addition to the previously discussed
diencephalon co-expression, both TCF7L2 and PAX6 are also
expressed in the endocrine pancreas and involved in the regula-
tion of insulin expression and maintenance of glucose levels. Us-
ing the recent information about open chromatin sites in human
islet tissue (Gaulton et al. 2010), we were able to show that three of
the 12 sites identified in the TCF7L2 region were among our Pax6
target predictions for this gene (data not shown). These observa-
tions illustrate the power of transcription factor target screens for
the discovery and extension of regulatory networks.
Methods
Computational predictions
Manipulation of tools and data
The manipulation of data and automation of bioinformatic tools
was performed using Perl scripts, developed in-house and available
in the Supplemental Material.
Sequence retrieval and orthology definition
The gene orthology data between H. sapiens, M. musculus, and D.
rerio, with description and annotation of respective genomic locus
coordinates, were retrieved from Ensembl, using the Biomart tool
(http://www.ensembl.org/biomart/). Extended gene locus sequence,
spanning from 20 kb upstream of to 20 kb downstream from each
gene, was retrieved from Ensembl, using Perl scripts and the
Ensembl Perl API (http://www.ensembl.org/info/data/api.html).
The Ensembl assemblies used were the human NCBI36, the
mouse NCBIM37, and the zebrafish Zv7danRer5.
Identification and retrieval of evolutionarily conserved regions
To identify sequences that are evolutionarily conserved between
pairs of orthologous gene loci, interspersed repeats and low com-
plexity DNA sequences were first masked, using RepeatMasker
(Smit et al. 1996–2004). The masked sequences were then blasted
against each other with BLASTZ (Schwartz et al. 2003) using the
following conditions: H=2200, T=0,W=6, K=2200. This allowed us
to define the coordinates for conserved regions that were thenused
locally to extract the respective sequences.
Generation of hidden Markov models (HMMs) for the Pax6 binding site
Pax6 bibliography was mined to extract experimentally validated
binding sites for the Pax6(-5a) isoform (references are available in
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the Supplemental Material) We found a total of 29, of which 16
could be used to make species-specific forward and reverse com-
plemented HMMs, using the HMMER software package (Eddy
1998). The models were adjusted for species specificity to in-
corporate any differences in nucleotide frequency between species.
This was accomplished by generating null models that contain
such information for each one of the three species.
The selection of the 16 binding sites for generation of the
models was achieved by an iterative procedure that used HMMs
produced from the initial set of similar binding sites and identi-
fying others by similarity. The iterative procedure stopped when
none of the remaining sequences had significant sequence simi-
larity to the ones already selected, as assessed by manual in-
spection.
Generation of position weight matrices (PWMs) for the Pax6 binding site
We used the sequence information from the 16 experimentally
validated pax6 binding sites to define the PWM according to the
nucleotide occurrence at each position. A Perl script was used to do
this (see Supplemental Material).
Comparison of PWM- and HMM-based procedures
The genomic regions that are conserved between the species’ pairs
that were analyzedwere screened using hmmsearch (HMMER) and
patser, using the pax6 HMM and pax6 PWM, respectively. For
the HMM data, we split the data according to the threshold that
can be determined by screening known BSs with the model. We
then calculated percentile for all the results data sets and com-
pared them using Perl scripts to identify co-identification of the
same putative binding sites by both methods. The heatmap was
generated using the heatmap.2 function of R (http://www.r-project.
org/).
Identification of putative pax6 binding sites and of putative direct
gene targets
The conserved sequences were screened using the pax6 HMM
models in order to identify putative binding sites. The score
threshold used was species-specific and defined for each model as
the minimum score within the sequences that were used to gen-
erate the models. To select the putative binding sites further, we
removed those that overlapped exons, and used megablast (Zhang
et al. 2000) on the remaining ones to identify those at the center of
a 100-bp highly conserved sequence interval (with at least 70%
sequence similarity to an equivalent interval in its respective
orthologous locus in the other species).
The identification of the gene targets was based on the asso-
ciation of the predicted binding site with the extended locus in
which it is found.
Gene ontology over-representation
The gene ontology characterization of the target sets was per-
formed using the default parameters from g:Profiler (Reimand et al.
2007), as implemented in theweb site, http://biit.cs.ut.ee/gprofiler/,
providing as input the sets of mouse or human genes predicted to
be directly regulated by PAX6.
Gene expression characterization
The computational characterization of gene expression was per-
formed using the UniGene expression data (available from files in
ftp://ftp.ncbi.nih.gov/repository/UniGene/). The Ensembl gene
IDs were converted into UniGene IDs using the Biomart tool from
Ensembl (http://www.ensembl.org/), and these were used to parse
the expression data. We used a Monte-Carlo approach, with 5000
test sets for each species, to determine the statistical significance of
the results.
Analysis of the coverage of intergenic regions
For any of the genes that are conserved between either zebrafish
and human, or zebrafish and mouse, or for all the genes in any of
the three species, we identified the distance between them and the
nearest proximal or distal gene. This was performed using gene
data downloaded from Ensembl, using the Biomart tool and Perl
scripts developed in-house.
Zebrafish embryo collection
General maintenance, collection, and staging of zebrafish were
carried out according to The Zebrafish Book (Westerfield 2000). The
approximate stages are given in hours post fertilization (hpf) at
28°C and are determined according to morphological criteria.
Zebrafish whole mount in situ hybridization
Whole-mount in situ hybridization (WMISH) reactions were car-
ried out according to published protocols (Thisse et al. 1993), at 28
hpf. The riboprobes for the putative target genes were transcribed
from PCR templates, amplified from genomic DNA using the oli-
gonucleotides shown in Supplemental Table S1.
Mouse expression pattern analysis
Whole-mount in situ hybridization reactions were carried out
according to published protocols (Wilkinson 1992), using fetuses
at 11.5-d post coitum (E11.5). The riboprobes for the putative
target genes were transcribed from DNA amplicons defined for
Eurexpress II (http://www.eurexpress.org/). These were: Foxp2–
T9351, Tcfap2a–T6939, and Maf –T40542.
Antisense morpholino oligonucleotide injections
The pax6a and pax6b antisense morpholino oligonucleotides
(MO) (Gene Tools) were directed against the 59 sequence near the
start of translation (Supplemental Table S2). The embryos were
injected through the chorion of 1 to 2-cell stage embryos with
a volume of 1.4 nl to deliver a mass of 3.5 ng. For each MO, at
least 100 embryos were injected, and we ascertained that the
phenotype was fully penetrant and of consistent severity. Co-
injection of pax6a and pax6b morpholinos was also performed,
using the same final masses. Standard control morpholino-
injected embryos did not differ from wild type uninjected
embryos.
Chromatin immunoprecipitation and QPCR
Pax6 ChIP was performed using the protocol described by Sansom
and coworkers (Sansom et al. 2009), using 28-hpf zebrafish em-
bryos for the preparation of chromatin. The antibodies used were:
Pax6 antibody (B5790; Abcam) and rabbit control IgG -ChIPGrade
(ab46540; Abcam). The only modification was to dissociate em-
bryonic cells mechanically before fixing them for 30 min.
The relative occupancy values for both Pax6 and IgG ChIPs
were calculated by determining the apparent IP efficiency (ratios of
the amount of ChIP-enriched DNA over that of the input sample)
and normalized to the level observed at a control region (N3
neg—1 kb upstream of the sox2 enhancer N3), which was defined
as 1.0. The fold-enrichment was calculated by normalizing the
relative occupancy for Pax6 with the relative occupancy for IgG.
The primers used are shown in Supplemental Table S3.
Coutinho et al.
1356 Genome Research
www.genome.org
Zebrafish transient reporter transgenesis
The zebrafish transient reporter transgenics were generated as de-
scribed in Kleinjan et al. (2008), using the Tol2-2way system with
a reporter cassette containing the zebrafish gata2 minimal pro-
moter, GFP and a poly A, adapted from a similar construct from the
Becker laboratory (Navratilova et al. 2009). A putative 385-bp en-
hancer fragment was PCR-amplified from zebrafish genomic DNA
and cloned into the Gateway P4P1r entry vector using the fol-
lowing primers:
foxp2_attB4: 59-aggggacaactttgtatagaaaagttggcgcgccatgactttt
acagttgcagc-39
foxp2_attB1r: 59-aggggactgcttttttgtacaaacttgtgtctctggtcaccc
aagca-39
The predicted Pax6 binding site in the foxp2 enhancer (59-
atggaatttacagtgcgcctccagtagtaactccattcgg-39) was mutated using
the Quickchange II site-directed mutagenesis kit (Stratagene) with
the following mismatch oligonucleotides: 59-atggaatttacagtgcta
caccagtagtaactccatttcccatcgg-39 and 59-ggaaatggagttactactggtgtagc
actgtaaattccatacagcca-39.
Western blot analysis
Ice-cold Ringer’s solution with ‘‘complete protease inhibitor
cocktail’’ tablets (Roche) was added to the zebrafish embryos. The
embryos were homogenized, using a Polytron PT 3100 system
(Thermo Fisher Scientific; setting 27,000 rpm, 30 sec), and the
homogenates were centrifuged at 13,000 rpm for 1 min. The su-
pernatants were collected and concentrated using Microcon YM-3
columns (Millipore).
Protein concentration was measured using the Bradford assay
(Bio-Rad) and NanoDrop 1000 spectrophotometer (Thermo Fisher
Scientific).
The proteins were resolved using a 4%–12%Nu-PAGE gel and
electroblotted onto Hybond-P PVDF membrane (Amersham/ GE
Healthcare). The PVDF membrane was blocked in 5% nonfat milk
in PBST (phosphate-buffered saline-Tween 20; 3.2 mM Na2HPO4,
0.5mMKH2PO4, 1.3mMKCl, 135mMNaCl, 0.05%Tween 20, pH
7.4) overnight at 4°C. The membrane was probed with anti-PAX6
antibody (AB5790; Abcam) for 1 h (1:5000 dilution in 13 TBS),
followed by donkey anti-rabbit secondary antibody conjugated to
horseradish peroxidase (GE Healthcare) (1:5000 dilution in 13
TBS). Immunoreactive protein bandswere detectedwith enhanced
chemiluminescence reagent (ECL) according to themanufacturer’s
instructions (AmershamPharmacia Biotech). Loadingwas checked
by stripping the blot with Restore Stripping Buffer (Pierce 21059)
and reprobing using anti-beta actin (Sigma A5441), followed by
HRP goat anti-mouse (SC2064; Santa Cruz Biotechnology) sec-
ondary antibody.
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